Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Blood (2023) 142 (Supplement 1): 4607.

https://doi.org/10.1182/blood-2023-187053

Published: 2023

Journal Articles

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Jessica M. Stempel, Allison J. Li, Alexander B Pine, Valentina Restrepo, Jan Philipp Bewersdorf, Maximilian Stahl, Nikolai A. Podoltsev, Lourdes Mendez, Rory M. Shallis, Deepa Rangachari, Alfred I Lee, Laura C. Michaelis, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2023-187163

Published: 2023

Journal Articles

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2023-188328

Published: 2023

Journal Articles

Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 324.

https://doi.org/10.1182/blood-2023-180299

Published: 2023

Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2023-182814

Published: 2023

Journal Articles

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Rohan Achar, Benjamin J. McCormick, Emily Dworkin, Emily Geramita, Annie Im, Anand Ashwin Patel, Talha Badar, Rory M. Shallis

Blood (2023) 142 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2023-179336

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Blood (2023) 142 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2023-186578

Published: 2023

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy

Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Rohan Achar, Rory M. Shallis, Danielle Bradshaw, Meaghan Standridge, Vamsi K. Kota, Talha Badar, Anand Ashwin Patel

Blood (2023) 142 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2023-185163

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Talha Badar, Ravi Narra, Alice Mims, Rory M. Shallis, Guilherme Sacchi De Camargo Correia, Cameron Hunter, Vamsi K. Kota, Shreya Desai, Anand Ashwin Patel, Adam S Duvall, Neil Palmisiano, Emily K Curran, Omer Zulfa, Anjali S. Advani, Ehab L. Atallah, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2023-188188

Published: 2023

Journal Articles

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Blood (2023) 142 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2023-186875

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2023-177758

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy

Cameron Hunter, Wei Cheng, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, Lisa Barbarotta, Rory M. Shallis

Blood (2023) 142 (Supplement 1): 589.

https://doi.org/10.1182/blood-2023-182989

Published: 2023

Journal Articles

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Jan Philipp Bewersdorf, Kishan K. Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Scott F. Huntington, Amer M. Zeidan

Blood (2022) 139 (11): 1766–1770.

https://doi.org/10.1182/blood.2021014401

Published: 2022

Includes: Supplemental data

NARROW

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Outcomes of Patients Receiving Intensive Therapy for Acute Myeloid Leukemia Relapsed after/Refractory to Frontline Less-Intensive Therapy

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Feasibility, Safety and Predictors of Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia Discharged “Early” after Intensive Induction Therapy

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only